Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Liebl

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|February 7, 2009
Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE studyStephen Jones, Marian Benroubi, Conxa Castell, et al.
Clinical Therapeutics|October 8, 2009
Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysisJaime A Davidson, Andreas Liebl, Jens S Christiansen, et al.
Current Medical Research and Opinion|February 24, 2011
Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countriesAndreas Liebl, Stephen Jones, Marian Benroubi, et al.
Drugs|July 24, 2012
Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findingsAndreas Liebl, Vinay Prusty, Paul Valensi, et al.
Diabetes Care|February 3, 2011
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialTim Heise, Cees J Tack, Robert Cuddihy, et al.
Journal of Diabetes Science and Technology|January 30, 2023
Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 DiabetesAthena Philis-Tsimikas, Vanita R Aroda, Christophe De Block, et al.
Diabetology & Metabolic Syndrome|February 7, 2014
Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational studyJean-François Yale, Taner Damci, Marcel Kaiser, et al.
Diabetes, Obesity & Metabolism|May 3, 2026
Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 DiabetesLisa Connery, Julio Rosenstock, Neda Rasouli, et al.
Journal of Diabetes Science and Technology|August 12, 2016
SPECTRUMBernhard Gehr, Martin Holder, Bernhard Kulzer, et al.
Drugs|January 22, 2020
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 DiabetesStewart Harris, Martin J Abrahamson, Antonio Ceriello, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|February 7, 2009
Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE studyStephen Jones, Marian Benroubi, Conxa Castell, et al.
Clinical Therapeutics|October 8, 2009
Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysisJaime A Davidson, Andreas Liebl, Jens S Christiansen, et al.
Current Medical Research and Opinion|February 24, 2011
Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countriesAndreas Liebl, Stephen Jones, Marian Benroubi, et al.
Drugs|July 24, 2012
Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findingsAndreas Liebl, Vinay Prusty, Paul Valensi, et al.
Diabetes Care|February 3, 2011
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialTim Heise, Cees J Tack, Robert Cuddihy, et al.
Journal of Diabetes Science and Technology|January 30, 2023
Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 DiabetesAthena Philis-Tsimikas, Vanita R Aroda, Christophe De Block, et al.
Diabetology & Metabolic Syndrome|February 7, 2014
Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational studyJean-François Yale, Taner Damci, Marcel Kaiser, et al.
Diabetes, Obesity & Metabolism|May 3, 2026
Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 DiabetesLisa Connery, Julio Rosenstock, Neda Rasouli, et al.
Journal of Diabetes Science and Technology|August 12, 2016
SPECTRUMBernhard Gehr, Martin Holder, Bernhard Kulzer, et al.
Drugs|January 22, 2020
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 DiabetesStewart Harris, Martin J Abrahamson, Antonio Ceriello, et al.
Pageof 5